| Literature DB >> 33371088 |
Xi Xu1, Yun-Feng Zhu, Tao Lv, Jin-Li Zheng, Yong-Kun Li, Bo-Han Zhang, Li Jiang, Jia-Yin Yang.
Abstract
ABSTRACT: To compare the difference between University of Wisconsin (UW) solution and histidine-tryptophan-ketoglutarate (HTK) solution in adult living donor liver transplantation (LDLT).This study included LDLT patients at the Liver Transplantation Center of West China Hospital of Sichuan University from November 2001 to June 2018. These patients were classified into 2 groups depending on the use of the different preservation solutions, and the confounding factors between the 2 groups were eliminated by propensity score matching. Finally, the incidence of complications; serum examination at postoperative days 1, 3, 5, 7, 14, 21, and 30; and the overall survival rate of the 2 groups were compared to observe whether there were any differences between the 2 preservation solutions.Of the 298 patients we screened, 170 were treated with UW solution and 128 with HTK solution. After propensity score matching, 106 pairs of patients were selected. In the comparison of the 2 groups, the length of intensive care unit stay in the UW group was significantly longer than that in the HTK group (P = .022), but there was no difference in the total length of hospital stay between the 2 groups (P = .277). No statistically significant difference was observed in the 2 groups in terms of the incidence of complications or postoperative examinations. However, the incidence of early allograft dysfunction in the HTK group was slightly lower than that in the UW group (HTK: UW = 14.1%: 20.7%), although the difference was not statistically significant. In terms of the overall survival rate, the 1, 3, and 5-year survival rates of the HTK group were 85.5%, 70.2%, and 65.1%, respectively, while the 1, 3, and 5-year survival rates of the UW group were 83.1%, 67.2%, and 59.8%, respectively, and there was no significant difference between the 2 groups.In conclusion, our study shows that UW solution and HTK solution are equivalent in perioperative safety, the recovery of transplanted liver function, the occurrence of postoperative complications and overall survival and can be safely and effectively applied in adult LDLT. If economic factors are taken into account, HTK can save costs to a certain extent.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33371088 PMCID: PMC7748334 DOI: 10.1097/MD.0000000000023584
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1Flow of study participants. HTK = histidine-tryptophan-ketoglutarate, LDLT = living donor liver transplantation, UW = University of Wisconsin.
Recipient demographics and surgically related factors before and after propensity score matching.
| Before matching | After matching | |||||
| Variable | HTK group (n = 128) | UW group (n = 170) | HTK group (n = 106) | UW group (n = 106) | ||
| Age | 43.0 ± 9.5 | 42.6 ± 8.7 | .708 | 43.3 ± 9.7 | 42.4 ± 9.1 | .494 |
| Sex (male) | 105 (82.0%) | 144 (84.7%) | .537 | 85 (80.2%) | 88 (83.0%) | .595 |
| BMI (kg/m2) | 22.2 ± 2.8 | 22.6 ± 3.2 | .246 | 22.3 ± 2.8 | 22.5 ± 3.2 | .647 |
| Creatinine (μmol/L) | 65 (50–76.4) | 67 (57–84) | .070 | 65 (53.2–76) | 65 (56.4–84) | .335 |
| ALB (g/L) | 32.5 (25.2–37.4) | 32.9 (26.8–39.0) | .346 | 33.2 (27.1–38) | 31.5 (27.1–37.3) | .400 |
| TB (μmol/L) | 37.15 (15.95–93.4) | 26.65 (13.9–59.4) | .025∗ | 35.2 (15.6–74.8) | 35.7 (17.0–68.6) | .956 |
| INR | 1.38 (1.21–1.71) | 1.37 (1.15–1.68) | .151 | 1.32 (1.2–1.6) | 1.44 (1.19–1.85) | .183 |
| MELD score | 14 (9.5–21.5) | 12 (8–17) | .029∗ | 13 (9–18) | 13.5 (10–18) | .506 |
| Child-Pugh score | 8 (7–10) | 8 (7–9) | .218 | 8 (7–10) | 8 (7–10) | .957 |
| Diagnosis | .882 | .882 | ||||
| Liver cirrhosis | 55 (42.9%) | 66 (38.9%) | 43 (40.6%) | 49 (46.2%) | ||
| Primary liver cancer | 50 (39.1%) | 77 (45.3%) | 46 (43.4%) | 41 (38.7%) | ||
| Alcoholic cirrhosis | 4 (3.1%) | 5 (2.9%) | 3 (2.8%) | 4 (3.8%) | ||
| Liver failure | 13 (10.2%) | 15 (8.8%) | 9 (8.5%) | 9 (8.5%) | ||
| Others | 6 (4.7%) | 7 (4.1%) | 5 (4.7%) | 3 (2.8%) | ||
| Anhepatic phase (min) | 89 (73–102) | 87 (70–105) | .949 | 88 (74–101.5) | 89 (75–107) | .886 |
| CIT (min) | 192 (116–270) | 177 (105–255) | .477 | 200 (115–270) | 190 (101–260) | .712 |
| Operation time (min) | 590 (500–660) | 641 (555–730) | .008∗ | 590 (500–665.5) | 600 (535–680) | .289 |
| Blood loss (mL) | 1500 (1000–3000) | 1500 (1000–3000) | .845 | 1500 (1000–3000) | 1500 (1000–2500) | .932 |
| PRBC transfusion (U) | 6 (1.5–8) | 4.75 (0–10) | .895 | 6 (1.75–8.75) | 6 (2–10.5) | .539 |
| Plasma transfusion (mL) | 800 (550–1450) | 1000 (600–1650) | .976 | 850 (575–1525) | 1050 (600–1800) | .611 |
| Platelet transfusion (U) | 0 (0–0) | 0 (0–0) | .539 | 0 (0–0) | 0 (0–0) | .822 |
| GRWR | 0.929% ± 0.184% | 0.932% ± 0.224% | .913 | 0.929% ± 0.189% | 0.911% ± 0.207% | .512 |
Donor demographic factors before and after propensity score matching.
| Before matching | After matching | |||||
| Variable | HTK group (n = 128) | UW group (n = 170) | HTK group (n = 106) | UW group (n = 106) | ||
| Age | 37.7 ± 10.2 | 36.7 ± 10.4 | .389 | 37.6 ± 10.4 | 37.4 ± 10.5 | .894 |
| Sex (male) | 61 (47.7%) | 109 (64.1%) | .004∗ | 57 (53.8%) | 59 (55.7%) | .783 |
| BMI (kg/m2) | 23.1 ± 2.5 | 23.0 ± 2.7 | .871 | 23.0 ± 2.5 | 23.0 ± 2.8 | .978 |
| TB (μmol/L) | 13.8 ± 5.3 | 14.6 ± 7.1 | .262 | 13.7 ± 5.3 | 15.2 ± 7.6 | .104 |
| AST | 23.9 ± 13.1 | 22.3 ± 9.8 | .238 | 23.6 ± 14.0 | 22.5 ± 10.5 | .527 |
| ALT | 25.3 ± 17.1 | 25.6 ± 18.7 | .871 | 25.0 ± 17.9 | 26.1 ± 20.6 | .684 |
| ABO compatibility | 128 (100%) | 169 (99.4%) | .218 | 106 (100%) | 106 (100%) | 1.000 |
| Operation time (min) | 424 ± 84 | 430 ± 87 | .564 | 420 ± 86 | 427 ± 84 | .578 |
Complication description of patients after propensity score matching.
| Variable | HTK group (n = 106) | UW group (n = 106) | |
| Postoperative respiratory support time (h) | 10 (6–25) | 10 (7.5–16) | .855 |
| Endotracheal re-intubation | 7 (6.6%) | 8 (7.5%) | .759 |
| Length of ICU stay (h) | 187 (142.5–301) | 239 (168–333) | .022∗ |
| Length of hospital stay (d) | 28 (18–36.5) | 28.5 (21–37.5) | .277 |
| Intraoperative complications | |||
| Cardiac arrest | 0 (0%) | 1 (0.9%) | 1.000 |
| Massive hemorrhage | 3 (2.8%) | 2 (1.9%) | 1.000 |
| Stenosis of the hepatic vein | 1 (0.9%) | 0 (0%) | 1.000 |
| Stenosis of the portal vein | 1 (0.9%) | 1 (0.9%) | 1.000 |
| Low blood pressure | 0 (0%) | 2 (1.8%) | .498 |
| Early postoperative complications | |||
| Abdominal bleeding | 5 (4.7%) | 5 (4.7%) | 1.000 |
| Hepatic artery embolization | 1 (0.9%) | 2 (1.8%) | 1.000 |
| Portal vein embolization | 2 (1.8%) | 2 (1.8%) | 1.000 |
| Stenosis of the hepatic vein | 1 (0.9%) | 0 (0%) | 1.000 |
| Multiple organ failure | 2 (1.8%) | 2 (1.8%) | 1.000 |
| Acute rejection | 3 (2.8%) | 0 (0%) | .236 |
| EAD | 15 (14.1%) | 22 (20.7%) | .205 |
| Late postoperative complications | |||
| Hepatic artery embolization | 0 (0%) | 0 (0%) | |
| Portal vein embolization | 0 (0%) | 1 (0.9%) | 1.000 |
| Stenosis of the hepatic vein | 1 (0.9%) | 0 (0%) | 1.000 |
| Chronic rejection | 4 (3.8%) | 2 (1.8%) | .679 |
| Biliary complications | 15 (14.1%) | 13 (12.2%) | .685 |
| Biliary stenosis | 13 (12.3%) | 9 (8.5%) | .368 |
| Biliary leakage | 4 (3.8%) | 5 (4.7%) | 1.000 |
Figure 2The development of postoperative total bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, glutamyl transpeptidase, and international normalized ratio at 1, 3, 5, 7, 14, 21, and 30 days after surgery. γGT = glutamyl transpeptidase, ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, HTK = histidine-tryptophan-ketoglutarate, INR = international normalized ratio, TB = total bilirubin, UW = University of Wisconsin.
Figure 3Patients survival and grafts survival after propensity score matching.